HomeNewsTrendsHealthChildren more resilient against COVID-19: Lancet study

Children more resilient against COVID-19: Lancet study

Researchers said that nearly a fifth of the pediatric population with COVID-19 did not exhibit any symptoms, and 21 percent of the children exhibited patchy marks of tissue injury on lung X-rays.

June 28, 2020 / 16:05 IST
Representative image

The majority of children with COVID-19 in 26 countries fared well clinically compared to adults, according to a review of studies which assessed research published during the first four months of the novel coronavirus pandemic.

Scientists, including those from The University of Texas in the United States, performed the largest systematic review to date of children and young adults with COVID-19, assessing the clinical data of more than 7,500 individuals.

In the findings, published in the journal EClinicalMedicine, a journal of The Lancet, they said nearly a fifth of the pediatric population with COVID-19 did not exhibit any symptoms, and 21 percent of the children exhibited patchy marks of tissue injury on lung X-rays.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

The researchers said 5.6 percent of the children assessed in the studies suffered from co-infections, such as flu, on top of COVID-19, and a little more than 3 percent were admitted to intensive care units.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Seven deaths were reported, according to the review research.

"Our data is compiled from 131 studies and encompasses 7,780 patients who span the pediatric age spectrum," said study senior author Alvaro Moreira from UT.

The research reported the most common symptoms, quantified laboratory findings, and described X-ray scan characteristics of children with COVID-19.

"Furthermore, we summarise treatments that were administered and offer an initial glimpse of a handful of patients who met the US Centers for Disease Control and Prevention (CDC) criteria for multisystem inflammatory syndrome in children," Moreira said.

According to the study, the most frequent symptoms, similar to the adult population, were fever and cough — found in 59 and 56 percent of the pediatric population, respectively.

In 233 individuals, the scientists said a past medical history was noted with 152 children in the group presenting with compromised immune systems, or had underlying respiratory or cardiac disease.

"Although we are hearing about severe forms of the disease in children, this is occurring in very rare circumstances," Moreira said.

Also read | COVID-19 linked to increased risk of stroke: Study

Based on laboratory measures noted in the reviewed studies, the scientists said pediatric COVID-19 patients had abnormal levels of molecules signifying inflammation in the body like creatine kinase, interleukin-6, and procalcitonin.

According to the scientists, only a small number of patients met inclusion for multisystem inflammatory syndrome in children.

They said the disease condition in these children paralleled the extreme forms of COVID-19 seen in adults.

"Children with systemic inflammation had a significant decrease in the amount of lymphocytes in their blood," Moreira said.

COVID-positive children who didn't have the extreme form of the disease had 42 per cent of the immune cells called lymphocytes in their blood, versus 11 per cent in children with the multisystem syndrome, he added.

The scientists said kidney failure was seen in nine pediatric patients, liver failure also in nine, and shock in 19.

They said mechanical ventilation was required by 42 patients.

While the review research provides evidence that children with COVID-19 have an overall better prognosis, the scientists said further studies are needed to confirm the findings, and "better understand which patients are at increased risk for developing severe inflammation and multiorgan failure."

Click here for Moneycontrol’s full coverage of the novel coronavirus pandemic

PTI
first published: Jun 28, 2020 03:50 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347